Trial Information
Pharmacokinetic Study of Nilotinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor Showing Failure to Both Imatinib and Sunitinib
Inclusion Criteria:
- Patients with metastatic or unresectable gastrointestinal stromal tumor
- Patients receiving nilotinib after failure to imatinib and sunitinib
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Principal Investigator
Yoon-Koo Kang, M.D., PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Asan Medical Center
Authority:
Korea: Food and Drug Administration
Study ID:
AMC0902
NCT ID:
NCT00976612
Start Date:
January 2009
Completion Date:
December 2011
Related Keywords:
- Gastrointestinal Stromal Tumors
- Gastrointestinal stromal tumor
- pharmacokinetics
- nilotinib
- Gastrointestinal Stromal Tumors